Compare Merck & Co., Inc. (MRK) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs MasTec Inc — how do they compare? Merck & Co., Inc. trades at $132.94 (market cap $321.77B), while MasTec Inc trades at $282.92 (market cap $21.90B). The key difference: Merck & Co., Inc. is far larger — about 14.7× MasTec Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MRK | MTZ | |
|---|---|---|
Market Cap | $321.77B | $21.90B |
Sector | Health | Technology |
52-Week High | $131.84 | $437.51 |
52-Week Low | $77.60 | $172.51 |
Enterprise Value | $368.53B | $24.81B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
MasTec (MTZ) trades at $283.76, up 5.77% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported record Q2 2026 revenue of $4.374 billion, up 23% year-over-year, and raised its full-year outlook. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show resistance near $283.
The outlook remains positive due to robust infrastructure demand, a record $21.4 billion backlog, and strategic acquisitions like The Superior Group. Risks include execution challenges in communications segments and high valuation multiples. Earnings growth and backlog execution are key catalysts for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
